Noctiva regulatory update

FDA approved an NDA from Serenity for Noctiva desmopressin nasal spray to treat nocturia due to nocturnal polyuria in adults who awaken ≥2 times per night to urinate. Serenity also regained all rights to Noctiva after the company and Allergan plc (NYSE:AGN, Dublin, Ireland) terminated a 2010 deal granting Allergan exclusive, worldwide rights to the product for all indications, except primary nocturnal enuresis (see BioCentury, April 5, 2010). Allergan said the termination was due to “a shift in Allergan’s commercial priorities.”...